These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 5042921)

  • 21. A rapid micromethod for direct H-2 typing of mouse cultured lymphoid cells.
    Götze D; Ferrone S
    J Immunol Methods; 1972 Jan; 1(2):203-6. PubMed ID: 5079999
    [No Abstract]   [Full Text] [Related]  

  • 22. [Lymphocytes HLA antigens expressivity after neuraminidase treatment (author's transl)].
    de Mouzon A; Ohayon E; Oksman-Domejean F; Ducos J
    Ann Immunol (Paris); 1976; 127(5):687-701. PubMed ID: 984732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of complement in the microlymphocytoxicity test. Human and guinea pig complement].
    Májský A
    Cas Lek Cesk; 1980 Nov; 119(45):1210-5. PubMed ID: 7438183
    [No Abstract]   [Full Text] [Related]  

  • 24. Rate of desensitization to HL-A antibodies in phytohaemagglutinin (PHA) stimulated lymphocytes.
    Rugarli C; Scorza R; Sabbadini MG
    Boll Ist Sieroter Milan; 1974; 53(4):573-7. PubMed ID: 4476215
    [No Abstract]   [Full Text] [Related]  

  • 25. Further studies on the effect of neuraminidase on tumor cell transplantability.
    Sanford BH; Codington JF
    Tissue Antigens; 1971; 1(4):153-61. PubMed ID: 5154254
    [No Abstract]   [Full Text] [Related]  

  • 26. Heat-labile accessory factor involved in vaccinia virus plaque neutralization.
    O'Brien TC; Hannah JE; Tauraso NM
    Arch Gesamte Virusforsch; 1973; 40(3):366-74. PubMed ID: 4735532
    [No Abstract]   [Full Text] [Related]  

  • 27. 51Cr release microassays for histocompatibility antigens on normal and malignant cells.
    Kay RG; Sharpin RK; Brown KJ
    Transplantation; 1973 Sep; 16(3):246-50. PubMed ID: 4199581
    [No Abstract]   [Full Text] [Related]  

  • 28. The interaction of normal lymphocytes and cells from lymphoid cell lines (LCL). V. Cytotoxic properties of activated lymphocytes.
    Ling NR; Steel CM; Wallin J; Hardy DA
    Immunology; 1974 Feb; 26(2):345-58. PubMed ID: 4854906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
    Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
    J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
    [No Abstract]   [Full Text] [Related]  

  • 30. Rhesus lymphocyte alloantigens. II. Serologic, genetic, and chemical characteristics.
    Rogentine GN; Merritt CB; Vaal LA; Ellis EB; Darrow CC
    Transplant Proc; 1972 Mar; 4(1):21-31. PubMed ID: 4110959
    [No Abstract]   [Full Text] [Related]  

  • 31. Variation in susceptibility of a human lymphoid cell line to immune lysis during the cell cycle. Lack of correlation with antigen density and complement binding.
    Pellegrino MA; Ferrone S; Cooper NR; Dierich MP; Reisfeld RA
    J Exp Med; 1974 Aug; 140(2):578-90. PubMed ID: 4527075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The PLL gene and histocompatibility genotype in inbred and random-bred guinea pigs.
    Ellman L; Green I; Benacerraf B
    J Immunol; 1971 Aug; 107(2):382-8. PubMed ID: 5568769
    [No Abstract]   [Full Text] [Related]  

  • 33. Interactions of antibodies and effector cells in immunity against tumours.
    Allison AC
    Ann Inst Pasteur (Paris); 1972 Apr; 122(4):619-31. PubMed ID: 5050872
    [No Abstract]   [Full Text] [Related]  

  • 34. Rat alloantibody responses against strong and weak histocompatibility antigens.
    Miller C; DeWitt C
    J Immunol; 1972 Nov; 109(5):919-26. PubMed ID: 5079095
    [No Abstract]   [Full Text] [Related]  

  • 35. Complement sensitivity of neuraminidase-treated lymphoid cells.
    Ray PK; Gewurz H; Simmons RL
    Transplantation; 1971 Oct; 12(4):327-9. PubMed ID: 4107114
    [No Abstract]   [Full Text] [Related]  

  • 36. Studies on pure red cell aplasia. VI. Development of two-stage erythroblast cytotoxicity method and role of complement.
    Zaentz SD; Krantz SB
    J Lab Clin Med; 1973 Jul; 82(1):31-43. PubMed ID: 4123985
    [No Abstract]   [Full Text] [Related]  

  • 37. Specific enhancement of the cytotoxic titre with regard to complement source and cytotoxicity test systems.
    Adolphs HD
    Experientia; 1972 May; 28(5):567-9. PubMed ID: 5040810
    [No Abstract]   [Full Text] [Related]  

  • 38. Carbohydrate inhibition studies of the naturally occurring human antibody to neuraminidase-treated human lymphocytes.
    Rogentine GN; Plocinik BA
    J Immunol; 1974 Sep; 113(3):848-58. PubMed ID: 4528455
    [No Abstract]   [Full Text] [Related]  

  • 39. Sialomucinous coating of normal and malignant cells.
    Ray PK; Simmons RL
    Surg Forum; 1971; 22():101-3. PubMed ID: 5121307
    [No Abstract]   [Full Text] [Related]  

  • 40. Antigenic alteration of lymphoblastic leukemic cells induced by cell culture and hydrocortisone.
    Kollmorgen GM; Bundren JC; Cain WA; Carubelli R
    Cancer Res; 1972 Sep; 32(9):1900-4. PubMed ID: 4509041
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.